Crossmark

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)

Crossref DOI link: https://doi.org/10.1038/s41408-026-01452-8

Published Online: 2026-03-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wei, Juying https://orcid.org/0000-0002-3758-8931
Cai, Qingqing https://orcid.org/0000-0001-5447-3282
Zhang, Liling

Zou, Liqun

Li, Zengjun

Zhou, Keshu

Wu, Huijing

Qiu, Lihua

Su, Liping

Ding, Kaiyang

Zhou, Hui

Yu, Li

Li, Fei

Li, Wenyu

Lin, Li’e

Xiao, Qing

Wang, Erhua

Jing, Hongmei

Zheng, Meifang

Zhang, Hongyu

Gao, Yuhuan

Gao, Da

Chen, Lijia

Jin, Jie https://orcid.org/0000-0002-8166-9915
License Information

Text and Data Mining valid from 2026-03-17

Version of Record valid from 2026-03-20
More Information

Article History

Received: 21 August 2025

Revised: 17 December 2025

Accepted: 9 February 2026

First Online: 17 March 2026

Competing interests

: This study was sponsored by Dizal Pharmaceutical. LC reported employment by Dizal Pharmaceutical. All remaining authors have declared no conflicts of interest.

Document is current

Any future updates will be listed below